Geographic and Product Information (Tables)

12 Months Ended

Dec. 31, 2011

Geographic and Product Information

Schedule of revenues and long-lived assets by geographic area

Revenues	2011		2010		2009
United States	$	2,860,935	$	2,188,562	$	1,732,179
Europe		1,571,088		1,266,791		908,130
All other		410,047		170,392		49,584
Total revenues	$	4,842,070	$	3,625,745	$	2,689,893

Long-Lived Assets (1)	2011		2010
United States	$	299,561	$	342,575
Europe		197,204		158,938
All other		9,277		8,406
Total long lived assets	$	506,042	$	509,919

(1)

Long-lived assets consist of net property, plant and equipment.

Schedule of total revenues from external customers by product

	2011		2010		2009
REVLIMID®	$	3,208,153	$	2,469,183	$	1,706,437
VIDAZA®		705,327		534,302		387,219
THALOMID®		339,067		389,605		436,906
ABRAXANE®		385,905		71,429		-
ISTODAX®		30,921		15,781		-
ALKERAN®		-		-		20,111
Other		30,317		28,138		16,681
Total net product sales		4,699,690		3,508,438		2,567,354
Collaborative agreements and other revenue		19,500		10,540		13,743
Royalty revenue		122,880		106,767		108,796
Total revenue	$	4,842,070	$	3,625,745	$	2,689,893

Schedule of customer concentration risk based on total revenues and net accounts receivable

	Percent of Total Revenue									Percent of Net Accounts Receivable
Customer	2011			2010			2009			2011			2010
Amerisource Bergen Corp.		12.6	%		9.8	%		10.9	%		3.9	%		4.6	%
CVS / Caremark		8.0	%		9.9	%		11.6	%		4.0	%		6.2	%